

Technologist presentation

Cardiac metabolism with hyperpolarized [1-¹³C]pyruvate: a feasibility study in mini-pig with a large dose injection

Luca Menichetti¹, Francesca Frijia², Vincenzo Lionetti³,
Maria Filomena Santarelli¹, Jan Henrik Ardenkjaer Larsen⁴,
Giulio Giovannetti¹, Vincenzo Positano^{*2}, Daniele De Marchi²,
Giovanni Aquaro², Manuela Campan³, Valentina Hartwig⁵,
Matteo Milanese², Fabio A Recchia⁶, Luigi Landini² and Massimo Lombardi²

Address: ¹Institute of Clinical Physiology, National Council of Research, Pisa, Italy, ²"G. Monasterio" Foundation, Pisa, Italy, ³Sector of Medicine, Scuola Superiore Sant'Anna, Pisa, Italy, ⁴GE Healthcare, Huginvej 8, 3400, Hillerod, Denmark, ⁵Department of Electrical Systems and Automation, University of Pisa, Pisa, Italy and ⁶Department of Physiology, New York Medical College, Valhalla, New York, NY, USA

* Corresponding author

from 13th Annual SCMR Scientific Sessions
Phoenix, AZ, USA. 21-24 January 2010

Published: 21 January 2010

Journal of Cardiovascular Magnetic Resonance 2010, **12**(Suppl 1):T7 doi:10.1186/1532-429X-12-S1-T7

This abstract is available from: <http://jcmr-online.com/content/12/S1/T7>

© 2010 Positano et al; licensee BioMed Central Ltd.

Introduction

MRI with hyperpolarised ¹³C represents a promising modality for *in vivo* spectroscopy and it could provide a unique opportunity for non invasive assessment of cardiac regional metabolism.

Purpose

The aim of this work is to study real time *in vivo* cardiac metabolism after intravenous (i.v.) injection of hyperpolarized [1-¹³C]-pyruvate in a large animal model with a clinical 3T scanner.

Methods

Animal model

Four normal male mini-pigs (35 kg) were maintained under deep sedation with midazolam (0.1 mg/kg/h i.v.) while ECG, temperature and arterial blood pressure were monitored (SA Instruments, New York USA).

Polarization

¹³C-1-pyruvate Hyperpolarization was performed using Dynamic Nuclear Polarization (*Hypersense*, Oxford Instruments, Oxford, UK). The final injection solution con-

tained 230 mM sodium [1-¹³C]pyruvate, 100 mM TRIS buffer, 0.27 mM Na₂EDTA and 20 microM Dotarem (Guerbet, Paris, France). Temperature of solution was about 37°C and pH = 7.6. A dose of 20 mL was administered over 10 s by manual injection.

MR studies

The mini-pigs underwent both ¹H MR imaging and hyperpolarized ¹³C MRS. The experiments were performed with a 3 T GE Signa HDx (GE Healthcare, Waukesha, WI, USA) scanner with a ¹³C quadrature birdcage coil (Rapid Biomedical, Würzburg, Germany). Anatomical imaging was acquired with the body coil and FIESTA sequence (FOV=35, FA=45, TE/TR=1.71 ms/3.849 ms).

¹³C dynamic spectra were acquired using elliptic-FIDCSI pulse sequence (bandwidth 5000Hz, 2048 pts, 10° FA). A long-axis slice of 20 mm was selected during excitation. Spectra covering the heart were acquired from the beginning of the injection of the hyperpolarized [1-¹³C]pyruvate, every 2 s, for 120 s.




Figure 1




Figure 2

Data processing

Data processing was performed by using MATLAB (The Mathworks, Inc., Natick, MA) and jMRUI software tools. The dynamic spectra were phase corrected by adjusting both zero-and first-order frequency-dependent phase components. Pyruvate, pyruvate hydrate, alanine, lactate, and bicarbonate were estimated by using AMARES algorithm included into jMRUI tools. Accordingly, time courses of metabolites are generated.

Results and discussion

Spectra obtained from the dynamic acquisition are shown in Figure 1. The [1-¹³C]pyruvate, [1-¹³C]pyruvate hydrate and metabolites peaks ([1-¹³C]lactate, [1-¹³C]alanine, and ¹³C-bicarbonate) have been detected and plotted. Figure 2 shows the *in vivo* time course of cardiac metabolites.

Conclusions

Imaging cardiac metabolism with hyperpolarized ¹³C is feasible with 3T MRI in an animal model that closely resembles the human heart phenotype.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp